Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 2,001–2,100 of 2,576
Risk factors for cognitive disorders in the elderly: A review
Abate, G., Ferrari-Ramondo, V., & Iorio, A. D. (1998) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(98)80002-2 · Cited by 7
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03297-z · Cited by 5
Palani, R. S., Williams, C. G., Thacker, D., Silvers, R., Qian, F., Weinreb, P. H., Mueller, L. J., Linse, S. S., & Griffin, R. G. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515673122 · Cited by 7
“Genetic studies have strongly implicated A β in AD pathogenesis ( 12 , 13 ).”
Elshazly, A. M., Sinanian, M. M., Elimam, D. M., & Zakaria, S. (2023) · Neuroglia · doi:10.3390/neuroglia4030014 · Cited by 6
Gu, X., Zhao, M., Han, X., & Liu, L. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105679 · Cited by 5
Eşmekaya, M. A., & Ertekin, B. (2024) · General Physiology and Biophysics · doi:10.4149/gpb_2024025 · Cited by 6
Gao, Y., Schedin‐Weiss, S., & Tjernberg, L. O. (2024) · Advanced technology in neuroscience . · doi:10.4103/atn.atn-d-24-00014 · Cited by 9
Zhao, L., Jiang, W., Zhu, Z., Pan, F., Xing, X., Zhou, F. L., & Zhao, L. (2024) · Foods · doi:10.3390/foods13244170 · Cited by 5
Alzheimer’s Disease and Diabetes
Brent, D. A., Gary, L., Aboud, Z., & Gordon, W. (2013) · InTech eBooks · doi:10.5772/54913 · Cited by 8
“An increased Aβ42/Aβ40 ratio has consistently been shown in fAD patients suggesting that Aβ42 is critical to AD pathogensis [330, 331].”
BackgroundJung, C., Uhm, K., Horike, H., Kim, M., Misumi, S., Ishida, A., Ueda, Y., Choi, E., Kim, Y., Michikawa, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141692 · Cited by 7
“Gene mutations in A PP, presenilin (PS)1, and PS2 have been found to selectively increase the A 42/40 ratio, which has been suggested to be the cause of AD [16–18].”
BackgroundPKR and PP1C Polymorphisms in Alzheimer’s Disease Risk
Palomer, E., ILL‐Raga, G., Tajes, M., Ramos‐Fernández, E., Bosch-Morató, M., Guivernau, B., Galán, J. J., Clarimón, J., Antúnez, C., Boada, M., et al. (2011) · Neuroscience & Medicine · doi:10.4236/nm.2011.23031 · Cited by 6
“Mutations in APP or presenilins (PS; part of the gamma secretase complex) trigger an inherited form of the disease, known as familiar AD (FAD) at early ages [8-10].”
BackgroundShin, Y. G., Hamm, L., Murakami, S., Buirst, K., Buonarati, M. H., Cox, A., Regal, K. A., Hunt, K. W., Scearce-Levie, K. A., Watts, R. J., et al. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0215-2 · Cited by 5
“Various methods have been developed for the quantitation of Ab peptides using enzyme linked immunosorbent assay (ELISA) or sandwich ELISA (Tahara et al. 1996; Gravina et al. 1995; Scheuner et al. 1996).”
MethodRösler, N., Wichart, I., & Jellinger, K. A. (2002) · Journal of Laboratory Medicine · doi:10.1046/j.1439-0477.2002.02031.x · Cited by 11
Stem Cell Technology for (Epi)genetic Brain Disorders
Riemens, R. J. M., Soares, E. S., Esteller, M., & Delgado‐Morales, R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_23 · Cited by 8
Brain targeting with lipidic nanocarriers
Antimisiaris, S. G., Mourtas, S., & Παπαδιά, Κ. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00007-3 · Cited by 6
Du, J., Li, S., Su, Y., Wang, H., Liu, H., & Cui, H. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110536 · Cited by 5
a prospective case-cohort study
van Oijen, M., Albert Hofman, D., Breteler, M. M. B., Koudstaal, P. J., & Soares, H. D. (2006) · Cited by 5
Structure–Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG
Nakamura, R., Akizawa, T., & Konishi, M. (2022) · Biomolecules · doi:10.3390/biom12121766 · Cited by 5
“Therefore, Aβ42 is predicted to be a potentially effective target for drug therapy.”
InfluentialApolipoprotein E4 inhibits γ‐secretase activity via binding to the γ‐secretase complex
Sun, Y., Islam, S., Gao, Y., Nakamura, T., Zou, K., & Michikawa, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15750 · Cited by 6
Protein Degradation in Alzheimer’s Disease and Aging of the Brain
Tsuji, T., & Shimohama, S. (2002) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-56373-7_4 · Cited by 5
Amyloid β-Peptide Neurotoxicity Assay Using Cultured Rat Cortical Neurons
Facci, L., & Skaper, S. D. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-536-7_6 · Cited by 5
Harasta, A. E., & Ittner, L. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_1 · Cited by 6
Yin, J., Feng, W. Q., Yuan, H., Yuan, J., Wu, Y., Liu, X., Jin, C., & Cheng, Z. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s186705 · Cited by 5
Stanyer, L., Betteridge, D. J., & Smith, C. C. T. (2004) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.07.005 · Cited by 5
Fukami, S., Iwata, N., & Saido, T. C. (2002) · Drug Development Research · doi:10.1002/ddr.10073 · Cited by 7
“The plasma Ab42 level is consistently elevated in all the familial AD, whereas such an elevation is rarely observed in sporadic AD cases [Scheuner et al., 1996].”
Neuronal Death in Alzheimer's Disease.
Yanagisawa, K. (2000) · Internal Medicine · doi:10.2169/internalmedicine.39.328 · Cited by 5
Shao, Y., Li, M., Wu, M., Shi, K., Fang, B., & Wang, J. (2015) · PubMed · Cited by 8
Amyloid .BETA. Peptides and Presenilins in the Pathogenesis of Alzheimer's Disease.
Iwatsubo, T. (1999) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.32.13 · Cited by 5
The 3xTg-AD Mouse Model: Reproducing and Modulating Plaque and Tangle Pathology
Sy, M., Kitazawa, M., & LaFerla, F. M. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_24 · Cited by 7
Yerer, M. B., Tiryaki, M., & Demirpolat, E. (2017) · Journal of Cellular Biotechnology · doi:10.3233/jcb-15035 · Cited by 5
Simultaneous acquisition of neuronal morphology and cytoarchitecture in the same Golgi-stained brain
Chen, X., Zhang, X., Zhong, Q., Sun, Q., Peng, J., Gong, H., & Yuan, J. (2017) · Biomedical Optics Express · doi:10.1364/boe.9.000230 · Cited by 6
Farlow, M. R. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10054-6 · Cited by 8
Julliams, A., Vanderhoeven, I., Kuhn, S., Broeckhoven, C. V., & Jonghe, C. D. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00402-4 · Cited by 5
Hwang, D. Y., Cho, J. S., Kim, C. K., Shim, S. B., Jee, S. W., Lee, S. H., Seo, S. J., Choi, S. Y., & Kim, Y. K. (2006) · NeuroMolecular Medicine · doi:10.1385/nmm:8:3:415 · Cited by 5
Molekulare Mechanismen der Alzheimer Erkrankung
Haass, C. (1999) · Springer eBooks · doi:10.1007/978-3-642-60228-3_4 · Cited by 7
Johnston, J. A., Jensen, M., Lannfelt, L., Walker, B., & Williams, C. H. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00834-4 · Cited by 6
Self-citationMultifocal Cortical Neurodegeneration in Alzheimer’s Disease
Vogt, B. A., Martin, A. D., Vrana, K. E., Absher, J. R., Vogt, L. J., & Hof, P. R. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_16 · Cited by 5
Genetics of Alzheimer's Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch43 · Cited by 6
Self-citationTransgenic animal model for Alzheimer’s disease
(1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.6.729 · Cited by 5
The role of amyloid beta 4-42 in the etiology of Alzheimer's disease
Bouter, Y. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4849 · Cited by 8
Amyloid Hypothesis and Alzheimer's Disease
Sun, X., & Zhang, Y. (2011) · InTech eBooks · doi:10.5772/28947 · Cited by 4
“…cytotoxicity hypothesis, which argues that the extracellular Aβ (eAβ), especially eAβ1-42, induces neuronal death, therefore, is one of the primary causes of AD (Yankner et al., 1990; Roses, 1996; Scheuner et al., 1996; Sinha and Lieberburg, 1999; De Strooper and Annaert, 2000; Wang et al., 2001).”
BackgroundWilson, C., Galeano, P., Remedi, M. M., Novack, G. V., Campanelli, L., Gastaldi, L., Miglietta, E. A., Rossi, A. H., Olivar, N., Brusco, L. I., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-35597-0 · Cited by 5
Transport pathways across the blood-brain barrier for waste clearance and drug delivery
Gröbner, L. S., & Pietrzik, C. U. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00812-7 · Cited by 4
“Depending on this cleavage, Aβ can contain between 39 to 43 amino acids [131, 132].”
Janus, C., Hernandez, C., deLelys, V., Roder, H. M., & Welzl, H. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_18 · Cited by 4
CRISPR-activated patient fibroblasts for modeling of familial Alzheimer's disease
Inoue, K. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.03.008 · Cited by 4
Kurth, V., Ogorek, I., Münch, C., López-Ríos, J., Ousson, S., Lehmann, S., Nieweg, K., Roebroek, A., Pietrzik, C. U., Beher, D., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104997 · Cited by 7
Johnson, E. A., Nowar, R., Viola, K. L., Huang, W., Zhou, S., Bicca, M. A., Zhu, W., Kranz, D. L., Klein, W. L., & Silverman, R. B. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402117122 · Cited by 5
Vers un diagnostic biologique de la maladie d’Alzheimer et des syndromes apparentés
Krolak‐Salmon, P., Seguin, J., Perret‐Liaudet, A., Desestret, V., Vighetto, A., & Bonnefoy, M. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.01.029 · Cited by 10
Bitan, F. R. A. G. (2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608058525114020014 · Cited by 5
“Although such high Aβ concentrations used to generate βamy balls are unlikely to occur in vivo [22, 269], it was argued that these concentrations could possibly occur locally at microfoci circumscribing the amyloid plaques in AD brain [39].”
BackgroundImmunotherapy Against N-Truncated Amyloid-β Oligomers
Bayer, T. A., & Wirths, O. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_3 · Cited by 4
Pathogenesis of Alzheimer’s Disease
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_162-1 · Cited by 5
The Aβcentric Pathway of Alzheimer’s Disease
Villemagne, V. L., Cappai, R., Barnham, K. J., Cherny, R. A., Opazo, C., Novakovic, K. E., Rowe, C. C., & Masters, C. L. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_2 · Cited by 18
Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders
Aziz, O., Bürli, R. W., Fischer, D. F., Frearson, J. A., & Wall, M. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50004-0 · Cited by 6
Prospects and Challenges for Alzheimer Therapeutics
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00023-x · Cited by 5
Modulating Role of TTR in Aβ Toxicity, from Health to Disease
Cardoso, I., Santos, L. M., & Alemi, M. (2016) · InTech eBooks · doi:10.5772/63194 · Cited by 8
Design of Inhibitors of Amyloid-β Misfolding and Aggregation for Alzheimer's Therapy
Estrada, L. D., Lasagna‐Reeves, C. A., & Soto, C. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_15 · Cited by 6
“These mutations are known to either increase formation of total Aβ or Aβ42 or to increase amyloidogenicity of the peptide (Table 1) (Hardy & Selkoe; Scheuner et al., 1996).”
BackgroundShi, C., Cha, J., Gong, J.-Y., Wang, S., Zeng, P. H., Lian, J.-J., Zhang, B., Hua, Q., Lv, J., Du, C., et al. (2022) · Cells · doi:10.3390/cells11061004 · Cited by 4
Towards mechanistic models of mutational effects: Deep learning on Alzheimer’s Aβ peptide
Wang, B., Razavi, S., & Gamazon, E. R. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.03.051 · Cited by 5
Chen, M., Wang, J., & Ming, C.-R. (2012) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-5374.2012.09.004 · Cited by 4
Membrane‐targeted strategies for modulating APP and Aβ‐mediated toxicity
Price, K. A., Crouch, P. J., Donnelly, P. S., Masters, C. L., White, A. R., & Curtain, C. C. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00642.x · Cited by 4
Peña, I. D., Ahn, H. S., Shin, C., & Cheong, J.-H. (2011) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2011.19.1.009 · Cited by 6
Molecular Aspects of Memory Dysfunction in Alzheimer’s Disease
Chin, J., Roberson, E. D., & Mucke, L. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00015-2 · Cited by 5
Effects of δ-Catenin on APP by Its Interaction with Presenilin-1.
Dai, W., Ryu, T., Kim, H., Jin, Y. H., Cho, Y.-C., & Kim, K. (2019) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0273 · Cited by 4
Padarti, A., Abou‐Fadel, J., & Zhang, J. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.129977 · Cited by 4
Farlow, M. R. (2007) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000267235.69379.07 · Cited by 16
Jaikaran, E. T. A. S., Marcon, G., Lévesque, L., George‐Hyslop, P. S., Fraser, P. E., & Clark, A. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.13.2137 · Cited by 5
γ-Secretase Inhibitors: From Chemical Probes to Drug Development
Hur, J., Gertsik, N., Johnson, D. S., & Li, Y.-M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00004-6 · Cited by 4
Biochemical aspects of dementias
Höck, C. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/chock · Cited by 10
Phospholipid composition and levels are not altered in fibroblasts bearing presenilin-1 mutations
Murphy, E. J., Zhang, H., Sorbi, S., Rapoport, S. I., & Gibson, G. E. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00257-4 · Cited by 4
Hayashi, Y., Fukatsu, R., Tsuzuki, K., Yoshida, T., Sasaki, N., Kimura, K., Yamaguchi, H., George‐Hyslop, P. S., Fujii, N., & Takahata, N. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00027-4 · Cited by 4
Cellular and molecular basis of b-amyloid precursor protein metabolism
Xu, H. (2000) · Frontiers in bioscience · doi:10.2741/a497 · Cited by 5
Qi, W., Long, Y., Li, Z., Zhao, Z., Shi, J., Xie, W., Wang, L., Tan, Y., Zhou, T., Liang, M., et al. (2025) · eLife · doi:10.7554/elife.99462.3 · Cited by 6
Johansson, C., Þórðardóttir, S., Laffita‐Mesa, J. M., Pannee, J., Rodriguez‐Vieitez, E., Zetterberg, H., Blennow, K., & Graff, C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01574-w · Cited by 4
Johansson, C., Koenig, T. W., Smailović, U., Hallström, V., Jelić, V., & Graff, C. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103879 · Cited by 3
Cai, J., Zhang, Q., Li, J., Yang, C., Li, Y., Yao, H., & Meng, L. (2026) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2026.109249 · Cited by 3
Status of Alzheimer’s and Parkinson’s Disease Detections and Treatments
Nguyen, P. H., & Derreumaux, P. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00096 · Cited by 5
Utility of animal models of Alzheimer's disease in food bioactive research
Lange, K. W. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2020.13255 · Cited by 3
Bustos, L. M., & Sattler, R. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1075805 · Cited by 4
“Identification of genetic variants in the APP, PSEN1 and PSEN2 genes associated with familial AD, were found to favor the longer Aß42 peptide and enhance its production (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991; Citron et al., 1992; Hendriks et al., 1992; Mullan et al., 1992; Cai et al.,…”
BackgroundChen, L., Meng, B., Xie, Y. F., Yao, Z., Chen, H., & Dong, Z. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404799 · Cited by 5
Baek, S., Lee, J. C., Byun, B. H., Park, S. Y., Ha, J. H., Lee, K. C., Yang, S., Lee, J., Hong, S., Han, G., et al. (2025) · Experimental Neurobiology · doi:10.5607/en25008 · Cited by 4
Jia, C., Sun, Y., Chen, J., & Liu, X. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00895f · Cited by 3
Kavitha, J. M., Sindhu, K. S., & Abi, T. G. (2025) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2025.115486 · Cited by 3
Li, A. (2013) · Hereditary Genetics · doi:10.4172/2161-1041.1000e105 · Cited by 3
“AD is characterized clinically by cognitive decline accompanied by neuronal loss and the formation of neurofibrillary tangles (NFTs) and insoluble toxic amyloid plaques in the brain [21].”
Backgroundalzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Polyphenols as Potential Therapeutic Drugs in Neurodegeneration
de Laureto, P. P., Palazzi, L., & Acquasaliente, L. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89575 · Cited by 4
Targeting angiogenesis, inflammation, and oxidative stress in Alzheimer's diseases
Bhandari, M., Tiwari, R. K., Chanda, S., & Bonde, G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13587-3.00003-5 · Cited by 5
Hendricks, E. L., & Liebl, F. L. W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300255 · Cited by 4
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Wiltfang, J. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4086-7 · Cited by 3
Alzheimer's disease: Mechanisms and development of therapeutic strategies
Tabira, T. (2003) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1444-1586.2003.00082.x · Cited by 3
Heyn, S. N., & Vulliet, P. R. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02312-5 · Cited by 3
The presenilins as potential drug targets in Alzheimer’s disease
Cupers, P., Annaert, W. G., & Strooper, B. D. (1999) · Emerging Therapeutic Targets · doi:10.1517/14728222.3.3.413 · Cited by 3
Mosser, S., Gerber, H., & Fraering, P. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15143 · Cited by 3
“This APP-swe double mutation is immediately adjacent to the β-secretase (BACE) site in APP and causes increased processing of APP by BACE associated with increased production and secretion of Aβ40 and Aβ42 (Citron et al., 1994; Nilsberth et al., 2001; Scheuner et al., 1996).”
BackgroundEarly Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging.
Farvadi, F., Hashemi, F., Amini, A., Vakilinezhad, M. A., & Raee, M. J. (2023) · PubMed Central · doi:10.22088/ijmcm.bums.12.2.172 · Cited by 6
Sehra, N., Parmar, R., Maurya, I. K., Kumar, V., Tikoo, K., & Jain, R. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129929 · Cited by 3
Peripheral Markers of Alzheimer’s
Percy, M. E., Andrews, D. F., & Potter, H. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_9 · Cited by 4
Wangler, M. F., Reiter, L. T., Zimm, G. G., Trimble-Morgan, J., Wu, J. Y., & Bier, E. (2011) · Protein & Cell · doi:10.1007/s13238-011-1073-7 · Cited by 5
“…for amyloid cleavage and FAD mutations in PSEN1 and PSEN2 lead to overproduction of the neurotoxic 42 amino acid form of β-amyloid (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Xia et al., 1997; Mehta et al., 1998; Oyama et al., 1998).”
BackgroundMetales de transición y enfermedad de Alzheimer
Opazo, C. (2005) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(05)74885-x · Cited by 3
Addressing the Complex Etiology of Alzheimer‘s Disease: the Role of P25/Cdk5
Mungenast, A. E., & Tsai, L. (2011) · Future Neurology · doi:10.2217/fnl.11.22 · Cited by 3
The Effects of Beta Amyloid Peptide 1-42 on Isolated Rat Hearts and Ileum Smooth Muscle
Yousefirad, N., Kaygısız, Z., & Aydin, Y. (2016) · Pharmacology · doi:10.1159/000448590 · Cited by 3
Cerebral lactate metabolism and memory: Implications for Alzheimer's disease
Harris, R. A. (2017) · Scholarship@Western (Western University) · Cited by 4
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.